ExodusPoint Capital Management LP Has $23.38 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

ExodusPoint Capital Management LP raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 554.8% during the fourth quarter, HoldingsChannel reports. The firm owned 137,550 shares of the specialty pharmaceutical company’s stock after acquiring an additional 116,542 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Jazz Pharmaceuticals were worth $23,384,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of JAZZ. Hilltop National Bank acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $36,000. LRI Investments LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $38,000. Danske Bank A S acquired a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $40,000. Geneos Wealth Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Jazz Pharmaceuticals by 1,383.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 332 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

JAZZ has been the topic of a number of research analyst reports. Wells Fargo & Company raised their target price on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Royal Bank Of Canada boosted their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. TD Cowen upped their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Piper Sandler increased their target price on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, May 22nd. Finally, UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the company from $188.00 to $307.00 in a research report on Tuesday, May 19th. Sixteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $246.06.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Heather Ann Mcsharry sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the transaction, the director directly owned 18,449 shares of the company’s stock, valued at approximately $4,446,209. The trade was a 9.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total value of $1,143,000.00. Following the transaction, the director directly owned 384,682 shares in the company, valued at $73,281,921. The trade was a 1.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,941 shares of company stock valued at $2,565,339 over the last 90 days. 4.10% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $226.88 on Wednesday. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. The company has a market capitalization of $14.25 billion, a PE ratio of -11,338.33, a P/E/G ratio of 0.20 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $243.32. The stock has a 50-day moving average price of $219.28 and a two-hundred day moving average price of $189.60.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The firm had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. Analysts expect that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.